Edwards Lifesciences (EW) Stock Forecast & Price Target

$86.81 -3.09 (-3.44%)

As of 12:27 PM Eastern

Compare

Edwards Lifesciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 23 Analyst Ratings

Sell
0

Hold
6

Buy
17

Based on 23 Wall Street analysts who have issued ratings for Edwards Lifesciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 23 analysts, 6 have given a hold rating, and 17 have given a buy rating for EW.

Consensus Price Target

$100.27
15.51% Upside

According to the 23 analysts' twelve-month price targets for Edwards Lifesciences, the average price target is $100.27. The highest price target for EW is $110.00, while the lowest price target for EW is $85.00. The average price target represents a forecasted upside of 15.51% from the current price of $86.81.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for EW and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Edwards Lifesciences and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EW Analyst Ratings Over Time

Type	Current Forecast 9/8/25 to 9/8/26	1 Month Ago 8/9/25 to 8/9/26	3 Months Ago 6/10/25 to 6/10/26	1 Year Ago 9/8/24 to 9/8/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	3 Strong Buy rating(s)	3 Strong Buy rating(s)
Buy	17 Buy rating(s)	17 Buy rating(s)	16 Buy rating(s)	12 Buy rating(s)
Hold	6 Hold rating(s)	6 Hold rating(s)	8 Hold rating(s)	10 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$100.27	$100.27	$95.96	$85.90
Forecasted Upside	15.51% Upside	11.85% Upside	11.65% Upside	7.00% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

EW Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

EW Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Edwards Lifesciences Stock vs. The Competition

Type	Edwards Lifesciences	Healthcare Companies	Broader Market
Consensus Rating Score	2.74	2.30	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	15.36% Upside	890.85% Upside	14.82% Upside
News Sentiment Rating	Positive News See Recent EW News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
7/28/2026	UBS Group 4 of 5 stars	Patrick Wood Not Rated	Initiated Coverage	Neutral ➝ Buy	$110.00	+32.20%
7/24/2026	Piper Sandler 2 of 5 stars	Adam Maeder 2 of 5 stars	Reiterated Rating	Overweight	$100.00 ➝ $101.00	+20.77%
7/24/2026	JPMorgan Chase & Co. 3 of 5 stars	Robbie Marcus 1 of 5 stars	Boost Target	Overweight	$100.00 ➝ $105.00	+24.95%
7/24/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Kratky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$87.00 ➝ $101.00	+20.77%
7/21/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joshua Jennings Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy
7/17/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold (C)
7/16/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Newitter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Hold	$90.00 ➝ $95.00	+9.28%
7/15/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$100.00 ➝ $105.00	+19.31%
7/13/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Shagun Singh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$100.00 ➝ $110.00	+19.09%
7/8/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joanne Wuensch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$101.00 ➝ $110.00	+16.05%
Get the Latest News and Ratings for EW and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.
7/6/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Vijay Kumar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$100.00	+7.66%
6/30/2026	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Marie Thibault Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$100.00 ➝ $110.00	+20.44%
4/27/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$104.00 ➝ $110.00	+30.64%
4/24/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	William Plovanic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Hold	$87.00 ➝ $85.00	+2.10%
4/24/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Rescott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$85.00 ➝ $87.00	+9.17%
4/1/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Peer Perform ➝ Outperform	$92.00	+14.91%
2/11/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Roman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$108.00 ➝ $95.00	+23.38%
2/11/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$96.00 ➝ $100.00	+31.67%
1/20/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Buy	$105.00 ➝ $110.00	+30.35%
11/3/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lee Hambright Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Market Perform	$90.00	+9.12%
11/3/2025	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jayson Bedford Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$96.00	+16.39%
10/31/2025	National Bank Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$92.00	+11.54%
10/29/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Taylor Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Hold ➝ Buy	$80.00 ➝ $98.00	+19.14%
10/8/2025	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Suraj Kalia Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
7/29/2025	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Strong-Buy
7/25/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
7/25/2025	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Pito Chickering Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$85.00 ➝ $94.00	+24.21%
7/15/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Wood Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$75.00 ➝ $81.00	+3.39%
7/10/2025	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Christine Dooley Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy
6/2/2025	Dbs Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	N. Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold
12/16/2024	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$82.00 ➝ $90.00	+20.97%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 12:27 PM ET.

Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, September 7, 2026. Please send any questions or comments about these Edwards Lifesciences pros and cons to contact@marketbeat.com.

Edwards Lifesciences
Bull Case

Here are some ways that investors could benefit from investing in Edwards Lifesciences Co.:

The company recently demonstrated strong financial performance by beating analyst expectations in its most recent quarterly report, delivering earnings per share of $0.78 against a consensus estimate of $0.74 and generating revenue of $1.74 billion, which exceeded the projected $1.70 billion. This beat was supported by a 13.6% increase in revenue compared to the same period last year, indicating robust demand for its structural heart disease products and critical care monitoring solutions.
Edwards Lifesciences Co. currently trades at a stock price of $90.00, which is below the consensus price target of $100.27 set by seventeen analysts who have rated the stock with a Buy rating. This discrepancy suggests that the market may be undervaluing the company relative to its peer group and future growth potential, offering a potential entry point for investors seeking upside.
Institutional investors are showing renewed confidence in the company, with the Virginia Retirement Systems purchasing a new position of 679,211 shares valued at approximately $61.4 million during the second quarter. Additionally, Vancity Investment Management Ltd increased its stake by 15.8%, and the Saudi Central Bank boosted its position by 88.4%, signaling that large-scale institutional capital is accumulating in the stock.
The company maintains a strong balance sheet with a low debt-to-equity ratio of 0.06 and a high current ratio of 4.52, which indicates that Edwards Lifesciences Co. has ample liquidity to cover its short-term obligations. This financial stability provides a safety margin for investors and supports the company's ability to invest in research and development without significant financial risk.
Edwards Lifesciences Co. is scheduled to present at the Deutsche Bank Healthcare Summit on September 16, 2026, where CEO Bernard Zovighian and CFO Doretta Mistras will discuss the company's strategic direction. This upcoming event may provide investors with fresh insights into the company's pipeline and growth strategy, potentially catalyzing further positive sentiment in the market.

Edwards Lifesciences
Bear Case

Investors should be bearish about investing in Edwards Lifesciences Co. for these reasons:

The stock is trading at a price-to-earnings ratio of 51.72, which is significantly higher than the broader market average, suggesting that the stock may be overvalued relative to its current earnings. This high valuation leaves little room for error if the company fails to meet its aggressive growth targets, potentially leading to a significant correction in the stock price.
Insider selling has been a persistent trend, with multiple executives including VP Annette Brüls, VP Daniel J. Lippis, and SVP Andrew M Dahl selling shares in recent months. For instance, Annette Brüls sold 2,644 shares at an average price of $89.98, and Daniel J. Lippis sold 619 shares at $92.03. While these sales may be part of pre-arranged trading plans, the consistent reduction in insider ownership could signal a lack of confidence in the stock's near-term upside.
Short interest in Edwards Lifesciences Co. has increased in recent months, with the number of shares shorted rising to 10,241,231 as of the most recent record date. This represents a 1.97% increase from the previous month and indicates that a significant portion of the market is betting against the stock, which could lead to increased volatility and downward pressure on the price.
The company's dividend yield is 0.00%, meaning that Edwards Lifesciences Co. does not pay a dividend to its shareholders. For income-focused investors, this lack of cash flow from dividends may be a drawback, especially when compared to other healthcare companies that offer regular dividend payments.
The stock's beta of 0.85 suggests that while it is less volatile than the overall market, it still carries a moderate level of risk. However, the recent decline in the stock price from its 52-week high of $96.29 to the current $90.00 indicates that the stock has experienced a pullback, which could be a sign of broader market uncertainty or company-specific challenges that have not yet been fully addressed.

EW Forecast - Frequently Asked Questions

According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for Edwards Lifesciences is $100.27, with a high forecast of $110.00 and a low forecast of $85.00.

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 6 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" EW shares.

According to analysts, Edwards Lifesciences's stock has a predicted upside of 15.51% based on their 12-month stock forecasts.

Over the previous 90 days, Edwards Lifesciences's stock had 1 upgrade by analysts.

Edwards Lifesciences has been rated by research analysts at BTIG Research, Citigroup, Evercore, JPMorgan Chase & Co., Leerink Partners, Mizuho, Piper Sandler, Royal Bank Of Canada, TD Cowen, Truist Financial, UBS Group, and Weiss Ratings in the past 90 days.

Analysts like Edwards Lifesciences more than other "healthcare" companies. The consensus rating for Edwards Lifesciences is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how EW compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Edwards Lifesciences Recommendations

MarketBeat monitors more than a dozen sources for Edwards Lifesciences analyst ratings, with the most recent rating issued on 7/28/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

EW Analyst Ratings Over Time

EW Analyst Recommendations By Month

EW Price Targets by Month

Edwards Lifesciences Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained

Edwards Lifesciences
Bull Case

Edwards Lifesciences
Bear Case

EW Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Edwards Lifesciences Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

EW Analyst Ratings Over Time

EW Analyst Recommendations By Month

EW Price Targets by Month

Edwards Lifesciences Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained

Edwards Lifesciences Bull Case

Edwards Lifesciences Bear Case

EW Forecast - Frequently Asked Questions

What is Edwards Lifesciences' forecast for 2026?

Should I buy or sell Edwards Lifesciences stock right now?

Does Edwards Lifesciences's stock price have much upside?

Has Edwards Lifesciences been upgraded by Wall Street analysts recently?

What analysts cover Edwards Lifesciences?

Do Wall Street analysts like Edwards Lifesciences more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Edwards Lifesciences Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Edwards Lifesciences
Bull Case

Edwards Lifesciences
Bear Case